Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Aug 03 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Indomethacin suppositories with a Competitive Generic Therapy designation. The Managing Director expressed satisfaction with the approval, highlighting the company's commitment to providing complex generic products to patients. Indomethacin suppositories are indicated for various inflammatory conditions and had significant annual sales in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 03, 2023, titled "Zydus receives Final Approval from the USFDA for Indomethacin Suppository with Competitive Generic Therapy (CGT) designation".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases